nasal spray News
-
Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia
HAMILTON, BERMUDA / ACCESSWIRE / January 21, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics announced today that Bentrio™ has been approved by the Medical Device Authority of Malaysia and is, therefore, cleared for commercialization in that ...
-
Altamira Therapeutics Establishes OTC Consumer Health Business Unit
HAMILTON, BERMUDA / ACCESSWIRE / February 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has established a new business unit, OTC Consumer Health, to support the ongoing global roll out of Bentrio™, its nasal spray for the protection against airborne viruses and allergens. ...
-
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of `Stalking Horse` Agreement to Facilitate Sale
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that ...
-
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an agreement for the marketing and distribution of Bentrio™ (the "Agreement"), its nasal spray for protection against airborne viruses and allergens, with Avernus ...
-
CD Formulation Announces Ability to Develop Liquid Dosage Forms
CD Formulation is known as a CRO service provider for custom pharmaceutical formulation projects. In a recent statement, the company announced its ability in liquid dosage forms development for customers worldwide who are looking for liquid dosage forms solutions for their drug development projects. There are different types of dosage forms, such as solid dosage form, liquid dosage form, ...
-
CD Formulation Announces Ability to Develop Liquid Dosage Forms
CD Formulation is known as a CRO service provider for custom pharmaceutical formulation projects. In a recent statement, the company announced its ability in liquid dosage forms development for customers worldwide who are looking for liquid dosage forms solutions for their drug development projects. There are different types of dosage forms, such as solid dosage form, liquid dosage form, ...
-
SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy
SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) today announced that it has been granted approval by Health Canada to conduct a multiCentre Phase II prevention and efficacy trial for a front-line antiviral prevention and early treatment for use against COVID-19. SaNOtize also announced that new tests conducted by the Institute for Antiviral ...
-
SaNOtize will be presenting at the Biotech Showcase™ Annual Conference on January 10th 2018
SaNOtize’s CEO, Dr. Gilly Regev, today announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square. Dr. Regev, CEO, will present at the Biotech Showcase™ as follows: Date: 10th, January , 2018 Time: 9:15am (PST) Room: Franciscan B ...
-
CD Formulation—An Expert to Solve Dosage Form Development Problems
Drugs must be properly formulated to bring out their best therapeutic effect and at the same time to ease as much administration burden as possible for patients. To select the most suitable dosage form, a lot of factors such as the properties of the drug substance and the project’s commercial needs should be taken into consideration. With a team of pharmaceutical experts, CD Formulation is ...
-
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 `TRAVERS` Clinical Trial of AM-125 for the Treatment of Acute Vertigo
HAMILTON, BERMUDA / ACCESSWIRE / February 14, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced completion of patient enrollment in Part B of the Phase 2 ‘TRAVERS' clinical trial evaluating intranasal betahistine (AM-125) in acute vertigo. The Company expects to release top-line results ...
-
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the geographic scope of its existing marketing and distribution agreement (the "Agreement") for Bentrio™ with Wellesta Holding Pte Ltd ("Wellesta") has been expanded. In addition to ...
-
Hospitals Battle Healthcare Acquired Infections (HAIs)
An article in the August issue of Infection Control and Hospital Epidemiology discusses how researchers identified contaminated nasal spray as the cause of an outbreak of Burkholderia cepacia in patients at a Denver children’s hospital. A recent news story from WLWT last week reported on the source of a Legionnaires’ disease outbreak at an Ohio hospital in 2010. WHEC in New York ...
-
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3 studies Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, ...
-
CD Formulation Provides Comprehensive Formulation Development and Analytical Services for the pharmaceutical Industry
Formulation development is of paramount importance for new drug development as it can determine patentability, lifecycle and, ultimately, the success of a pharmaceutical product. Fully aware of the challenges that may arise from this process, CD Formulation recently announces that it now provides a comprehensive range of formulation development and analytical services for the pharmaceutical ...
-
BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA
BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration (FDA). If the FDA has no further comments after the 30-day review period, BRIM will proceed to initiate the Phase 3 clinical trial in December. Based on its ...
-
Altamira Therapeutics Provides Update on RNA Therapeutics Program
HAMILTON, BERMUDA / ACCESSWIRE / January 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on its development activities in RNA therapeutics. Growing the Leadership Team As part of its ongoing repositioning around ...
-
Neurent Medical Closes $25 Million Series B Funding to Advance Innovative Chronic Rhinitis Treatment
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced it has closed a $25 million Series B financing. The round was led by new investor LSP, from its LSP HEF-2 fund, and co-led by Atlantic Bridge, investing from its Growth Fund IV. Fountain Healthcare Partners also participated as a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you